Tags

Type your tag names separated by a space and hit enter

Initial Clinical Results With a Novel Monofocal-Type Intraocular Lens for Extended Macular Vision in Patients With Macular Degeneration.
J Refract Surg. 2018 Nov 01; 34(11):718-725.JR

Abstract

PURPOSE

To determine the feasibility of a novel intraocular lens (IOL) designed to improve retinal image quality at up to 10° of retinal eccentricity and optionally provide retinal magnification in patients with macular disease.

METHODS

In this prospective, interventional pilot study, 8 eyes of 7 patients with bilateral dry age-related macular degeneration and 1+ or less cataract underwent phacoemulsification and capsular bag implantation of a single, injectable, hydrophobic acrylic IOL. Safety and efficacy were assessed by monitoring logMAR corrected distance and near visual acuity, intraocular pressure, specular microscopy, 80-point visual field testing, and anterior segment and macular optical coherence tomography at baseline and 1 week, 1 month, and 2 months postoperatively. Microperimetry was undertaken at baseline and 1 and/or 2 months postoperatively. Reading performance was assessed at baseline and 1 month postoperatively using the Minnesota low vision reading chart (MNREAD; Precision Vision, LaSalle, IL).

RESULTS

Safety outcomes were equivalent to standard monofocal IOLs. Visual acuities improved in all patients. Mean corrected distance visual acuity improved from 0.93 ± 0.22 preoperatively to 0.59 ± 0.25 at 2 months postoperatively. Mean reading speed increased from 28 ± 19 to 44 ± 31 words per minute. Mean microperimetry threshold sensitivities increased from 8.2 ± 4.6 to 12 ± 5.6 dB. Mean percentage of fixation points within a 4° circle increased from 77% ± 17% to 91% ± 11% with evidence for progressive movement of preferred retinal loci away from areas of geographic atrophy.

CONCLUSIONS

Initial results indicate this novel IOL has a safety profile comparable with standard IOLs. Visual benefits may exceed those obtained with existing technologies in patients with macular disease. Further work is required to determine the full potential of extended macular vision technology. [J Refract Surg. 2018;34(11):718-725.].

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Study
Journal Article

Language

eng

PubMed ID

30428091

Citation

Robbie, Scott J., et al. "Initial Clinical Results With a Novel Monofocal-Type Intraocular Lens for Extended Macular Vision in Patients With Macular Degeneration." Journal of Refractive Surgery (Thorofare, N.J. : 1995), vol. 34, no. 11, 2018, pp. 718-725.
Robbie SJ, Tabernero J, Artal P, et al. Initial Clinical Results With a Novel Monofocal-Type Intraocular Lens for Extended Macular Vision in Patients With Macular Degeneration. J Refract Surg. 2018;34(11):718-725.
Robbie, S. J., Tabernero, J., Artal, P., & Qureshi, M. A. (2018). Initial Clinical Results With a Novel Monofocal-Type Intraocular Lens for Extended Macular Vision in Patients With Macular Degeneration. Journal of Refractive Surgery (Thorofare, N.J. : 1995), 34(11), 718-725. https://doi.org/10.3928/1081597X-20180831-01
Robbie SJ, et al. Initial Clinical Results With a Novel Monofocal-Type Intraocular Lens for Extended Macular Vision in Patients With Macular Degeneration. J Refract Surg. 2018 Nov 1;34(11):718-725. PubMed PMID: 30428091.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Initial Clinical Results With a Novel Monofocal-Type Intraocular Lens for Extended Macular Vision in Patients With Macular Degeneration. AU - Robbie,Scott J, AU - Tabernero,Juan, AU - Artal,Pablo, AU - Qureshi,Muhammad A, PY - 2018/03/05/received PY - 2018/08/30/accepted PY - 2018/11/15/entrez PY - 2018/11/15/pubmed PY - 2019/1/15/medline SP - 718 EP - 725 JF - Journal of refractive surgery (Thorofare, N.J. : 1995) JO - J Refract Surg VL - 34 IS - 11 N2 - PURPOSE: To determine the feasibility of a novel intraocular lens (IOL) designed to improve retinal image quality at up to 10° of retinal eccentricity and optionally provide retinal magnification in patients with macular disease. METHODS: In this prospective, interventional pilot study, 8 eyes of 7 patients with bilateral dry age-related macular degeneration and 1+ or less cataract underwent phacoemulsification and capsular bag implantation of a single, injectable, hydrophobic acrylic IOL. Safety and efficacy were assessed by monitoring logMAR corrected distance and near visual acuity, intraocular pressure, specular microscopy, 80-point visual field testing, and anterior segment and macular optical coherence tomography at baseline and 1 week, 1 month, and 2 months postoperatively. Microperimetry was undertaken at baseline and 1 and/or 2 months postoperatively. Reading performance was assessed at baseline and 1 month postoperatively using the Minnesota low vision reading chart (MNREAD; Precision Vision, LaSalle, IL). RESULTS: Safety outcomes were equivalent to standard monofocal IOLs. Visual acuities improved in all patients. Mean corrected distance visual acuity improved from 0.93 ± 0.22 preoperatively to 0.59 ± 0.25 at 2 months postoperatively. Mean reading speed increased from 28 ± 19 to 44 ± 31 words per minute. Mean microperimetry threshold sensitivities increased from 8.2 ± 4.6 to 12 ± 5.6 dB. Mean percentage of fixation points within a 4° circle increased from 77% ± 17% to 91% ± 11% with evidence for progressive movement of preferred retinal loci away from areas of geographic atrophy. CONCLUSIONS: Initial results indicate this novel IOL has a safety profile comparable with standard IOLs. Visual benefits may exceed those obtained with existing technologies in patients with macular disease. Further work is required to determine the full potential of extended macular vision technology. [J Refract Surg. 2018;34(11):718-725.]. SN - 1081-597X UR - https://www.unboundmedicine.com/medline/citation/30428091/Initial_Clinical_Results_With_a_Novel_Monofocal_Type_Intraocular_Lens_for_Extended_Macular_Vision_in_Patients_With_Macular_Degeneration_ L2 - https://www.healio.com/doiresolver?doi=10.3928/1081597X-20180831-01 DB - PRIME DP - Unbound Medicine ER -